Hisgade (Suzhou) Biomedical Technology

About Hisgade (Suzhou) Biomedical Technology

Hisgade (Suzhou) Biomedical Technology, also known as Health Guard Biomed, is a medical device company established in 2020 and based in Suzhou, China. The firm is focused on the development and commercialization of implantable medical devices specifically for ophthalmic diseases. It operates an open laboratory and maintains an R&D center in Shanghai along with a machining center in Nantong, fostering collaboration with professional medical institutions.

The company's business model revolves around providing a product pipeline of implantable devices and complementary diagnostic and treatment equipment for conditions such as glaucoma, cataracts, and fundus lesions. Its primary product is the MicroCOGO® Trabecular Mesh Micro-Stent Drainage System, a device implanted in the eye to reduce intraocular pressure in adult patients with mild to moderate primary open-angle glaucoma. In addition to its surgical implants, the company offers the Haisiwei® Rebound Tonometer, a device for the daily monitoring of intraocular pressure, with plans to use recent funding to scale its production and commercialization.

Health Guard Biomed has successfully secured multiple rounds of funding, indicating investor confidence in its market position and product strategy. As of April 2024, the company had raised $14.5M and was in a revenue-generating stage. It completed a Series B funding round in July 2024, with participation from investors like Guohai Innovation Capital Investment Management and returning investor Sealand Innovation. Other notable investors include Delian Capital, TF Capital, BioTrack Capital, Banyan Pacific Capital, and Suzhou Industrial Park Venture Capital Fund.